Category: Business

Gb Sciences’ innovative approach harnesses the power of plant-based treatments as simplified mixtures that target dangerous hyperinflammatory responses to viral infections.

LAS VEGAS – December 22, 2022 – (Newswire.com)

Gb Sciences, Inc. (OTCQB:GBLX), a leading plant-inspired, biopharmaceutical research and development company, is developing cannabis-inspired anti-inflammatory therapeutics that address Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others. Over the two pandemic years, more than 540 million people across the world contracted COVID-19 and 6.3 million died from the hyperinflammatory side effects related to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral outbreaks that elicit these dangerous hyperinflammatory responses. 

The global anti-inflammatory therapeutics market size was estimated at USD 99.6 billion in 2021, according to Precedence Research, and is expected to hit USD 127.5 billion by 2030, with a registered CAGR of 4.5% from 2022 to 2030. Gb Sciences announced in May 2022 that FHI Clinical would consult and write the draft clinical trial protocol for a first-in-human trial of these proprietary cannabinoid-containing formulations. One key differentiator of Gb Sciences’ CRS therapeutic is the early-intervention and preventative opportunities for patients when they first discover they have been exposed to a virus that causes hyperinflammation. This therapeutic may also be useful for patients who are experiencing CRS as a side effect of certain new cancer therapeutics, such as Bispecific T-cell engaging (BiTE) single-chain antibody constructs and chimeric antigen receptor (CAR) T-cells.

“Our research shows promise for the potential use of cannabinoids within cannabinoid-containing mixtures as a treatment option for hyperinflammation. There is still a need for effective treatments to combat the hyperinflammatory effects of certain viruses. Our cannabis-inspired therapeutics were designed to reset the immune system after hyperinflammation has been triggered, providing relief by targeting our human immune response to a virus, without being tied to a specific variant or the virus itself,” said Andrea Small-Howard, President and Chief Science Officer of Gb Sciences.

Gb Sciences used PhAROS™, its proprietary AI-enabled drug discovery platform, to identify these therapeutic mixtures that were designed to reduce the levels of specific cytokines and pro-inflammatory processes triggered by viruses, while preserving the immune functions and cytokines necessary to fight viral infections. Gb Sciences recently published a white paper on their novel development program titled “Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics”; download it here. 

A proof-of-concept study completed by researchers at Michigan State University in 2021 found that Gb Sciences’ proprietary cannabis-inspired minimum essential mixtures (MEM) reduced cytokine release syndrome biomarkers. Gb Sciences’ MEM, containing either two or three cannabinoids each, reduced the levels of inflammatory biomarkers more than the sum of the anti-inflammatory effects of the single ingredients tested separately. The ratios of those cannabinoid molecules within the MEM formulations also greatly influenced their anti-inflammatory potential, the study reported. 

To learn more about Gb Sciences, visit www.gbsciences.com.

About Gb Sciences and GbS Global Biopharma

Gb Sciences, Inc. is a plant-inspired, biopharmaceutical research and development company creating patented disease-targeted formulations of cannabis- and other plant-inspired therapeutic mixtures for the prescription drug market through its Canadian subsidiary GbS Global Biopharma, Inc. The “plant-inspired” active ingredients in its therapeutic mixtures are synthetic homologues identical to the original plant compounds but produced under current Good Manufacturing Practices. Gb Sciences’ intellectual property portfolio contains six issued U.S. and three issued foreign patents, as well as 17 U.S. and 51 foreign patent-pending applications. In its drug development pipeline, Gb Sciences has five preclinical phase product development programs. Gb Sciences’ lead program for Parkinson’s disease is being prepared for a first-in-human clinical trial. Gb Sciences’ formulations for chronic pain, anxiety, and depression are currently in preclinical animal studies with researchers at the National Research Council Canada. The company also received positive preclinical proof-of-concept data supporting its complex mixtures for the treatment of Cytokine Release Syndrome, and its lead candidates will be optimized based on late-stage preclinical studies at Michigan State University. Gb Sciences’ productive research and development network includes distinguished universities, hospitals, and Contract Research Organizations. To learn more, visit www.gbsciences.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects,” “intends,” “plans,” “may,” “could,” “should,” “anticipates,” “likely,” “believes,” and words of similar import may identify forward-looking statements. These statements are not historical facts but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Contact Information:

Alexis Quintal

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Gb Sciences Identifies Novel Cannabis-Inspired Mixtures as Anti-Inflammatory Therapies Based on Proprietary AI-Enabled Drug Discovery Platform

New Suite of 3GPP Compatible Telecom Software Provides Significant Data Rate & Security

TM Technologies
SAN DIEGO …

BUFFALO GROVE, Ill. – December 21, 2022 – (Newswire.com)

PPC Flexible Pa…

ClickIT is part of the Clutch 1000 Global Companies in 2022 as a Top Software Development Company

ClickIT, a top 1000 Global Company Clutch badge…

WASHINGTON – December 20, 2022 – (Newswire.com)

Statement by Farah K. Ahmed, President & CEO, Fragrance Creators Association (Fragrance Creators), on the inclusion of long-awaited updates to federal cosmetics law in the FY2023 omnibus appropriations bill released earlier this morning: 

“Fragrance Creators applauds the inclusion of the “Modernization of Cosmetics Regulations Act” in the FY2023 omnibus appropriations bill, and we urge Congress to approve it this week. This will create a modern cosmetics regulatory framework—including for fragrances in cosmetics products—designed to advance sound science, safety, innovation, and consumer confidence. We thank Senators Murray, Burr, Collins and Feinstein and Representatives Pallone and McMorris Rodgers and their tireless staffs for championing this legislation. While we are pleased that cosmetics regulations are now coming in-line with the needs of the 21^st century, we remain concerned that future individual state actions could negatively impact competition, limit innovation, and cause consumer confusion.  Fragrance Creators looks forward to engaging with the Food and Drug Administration to ensure a strong federal role and proper implementation of the cosmetics modernization provisions as related to fragrance.”   

###

Fragrance Creators Association is the trade association representing the majority of fragrance manufacturing in North America. We also represent fragrance-related interests along the value chain. Fragrance Creators’ 60+ member companies are diverse, including large-, medium-, and small-sized companies that create, manufacture, and use fragrances and scents for home care, personal care, home design, fine fragrance, and industrial and institutional products, as well as those that supply fragrance ingredients, including natural extracts and other raw materials that are used in perfumery and fragrance mixtures. Fragrance Creators established and administers the Congressional Fragrance Caucus, ensuring ongoing dialogue with members of Congress and staff. We are an active participant in IFRA and have a designated representative on the IFRA Board to help ensure the association’s membership is represented in global discussions and the North American perspective is considered in global fragrance positions and policies. Fragrance Creators also produces The Fragrance Conservatory, the comprehensive digital resource for high-quality information about fragrance—www.fragranceconservatory.com. Learn more about Fragrance Creators at fragrancecreators.org—for people, perfume, and the planet.

Contact Information:

Katie Cross

[email protected]

Press Release Service
by
Newswire.com

Original Source:

Fragrance Creators Association Statement on Inclusion of the ‘Modernization of Cosmetics Regulations Act’ in the FY2023 Consolidated Appropriations Act

Funds will help The American Legion, Department of Florida as they continue to assist in recovery.

Founding Fathers Products Presenting Donation to…

KlimaDAO’s advanced selective retirement tool gives users unprecedented choice over digital carbon credits used for offsetting.

SAN FRANCISCO – December 20, 2022 – (Newswire.com)

KlimaDAO, the leading provider of digital carbon credits, has today announced the launch of its advanced retirement tool for carbon offsetting. The tool gives users the option to selectively filter, choose and retire carbon credits from over 20 million tonnes of available digital carbon credits. 

The tool is now available on KlimaDAO’s app, and it allows users to specify their preferred carbon credit criteria against hundreds of unique carbon projects from across the globe. Users have the option to select credit by “technology type”, “region” and “vintage” (i.e. the year the credit was created) to quickly filter available options and inform their selection. 

In a market that is typically challenging to navigate due to poor market accessibility and limited market data, the tool gives users the ability to easily access the available options for digital carbon credits based on their priorities in just a few clicks. 

Given the permissionless nature of the KlimaDAO ecosystem, the tool enables third parties to quickly meet their own needs, or those of their clients, without having to wait for suppliers to respond to requests. 

Sy Zygy, Product Lead at KlimaDAO, said, “The advanced selective retirement feature offers our users the ability to quickly filter carbon projects according to their offsetting requirements within minutes, without needing to undertake extensive desk-based research or waiting for suppliers to fulfill their needs, which can take weeks. By giving users optionality over KlimaDAO’s entire carbon credit supply, we can enable the market to function more efficiently for the benefit of all stakeholders.”

KlimaDAO will hold the ON SET Webinar series beginning in February 2023; the series will provide an introduction to the digital carbon market and provide product demonstrations for stakeholders interested in using digital carbon tools. Follow this link to sign-up for the Webinar. 

About KlimaDAO

KlimaDAO’s mission is to accelerate the delivery of climate finance globally by building the transparent, neutral, and public infrastructure needed to scale the Digital Carbon Market. KlimaDAO provides tools, products and services to make accessing this market easy for all users. Contact us by filling out this form. 

Contact Information:

Alex Taylor

Press

[email protected]

Press Release Service
by
Newswire.com

Original Source:

KlimaDAO Launches Advanced Selective Retirement for Carbon Credits

IRVING, Texas – December 20, 2022 – (Newswire.com)

It was early 2020 when Aziz “AJ” Jamal, CEO of Elite Cellular Inc. dba Elite Supply Chain Solutions, decided to make his company’s presence felt beyond the reverse logistics industry. He wanted to do more for the community his company calls home. Thus, “Elite Cares” was born.

Coincidentally, just a few short weeks after brainstorming the new initiative with other members of the leadership team, the world’s collective suffering at the hands of COVID-19 began. Naturally, this made Elite Cares even more imperative, which just wrapped up its third consecutive holiday season of giving back to the community. AJ went on to say, “Many businesses and individuals do their part for the community by making charitable donations. We want to do more, be more engaging, really care. People are hurting out there and we want to give more than just money. We want to devote our time and effort, too.”

Elite Cares – Timeline of Events

• February 2020 – Program inception
• March 2020 – Pandemic lockdown
• November 2020 
  • Collected one truckload of canned food for the North Texas Food Bank
  • Provided eight full turkey meals to families in need
• December 2021 – Collected half of a truckload worth of toys for Children’s Health
• November 22, 2022 – Senior management volunteered to prepare dinner at The Stewpot, a homeless service in Dallas
• November 23, 2022 – Elite Cellular staff volunteered to prepare breakfast and lunch at The Stewpot
• 2023 – Stay tuned! 

About Elite Cellular Inc.: Founded in 2010, Elite Cellular Inc. dba Elite Supply Chain Solutions is a reverse logistics company operating in the electronics industry. Elite Cellular is a premier player in the space and is an integral part of AT&T, T-Mobile, and Verizon’s supply chain for trade-in devices. Elite Cellular processes over one million devices per year in their Irving-based 60,000-square-foot warehouse. Additional locations in Dubai, Hong Kong, Colombia, and the Netherlands allow Elite Cellular to remarket these devices to their customers all around the globe. Elite Cellular is committed to the environment and is an R2-Certified entity within the Sustainable Electronics Recycling International (SERI) organization.

Contact Information:

April Garcia

Executive Assistant

[email protected]

(214) 956-0500

Press Release Service
by
Newswire.com

Original Source:

Elite Cares – Elite Cellular’s Impactful Initiative to Give Back

Impact Recycling Partners Meet the team at Impact Recycling Partners
PHILADELPHIA – December 20, 2022 – (Newswire….

DOWNERS GROVE, Ill. – December 20, 2022 – (Newswire.com)

Stenograph®, LLC announces that Claritas Depositions has selected its CaseTestify™ remote deposition platform and MAXScribe™ court reporting solution to meet the needs of an evolving industry. The legal transcript market is growing at a steady rate, and more depositions are occurring in a remote or hybrid fashion, creating a need for new solutions. As the leading technology provider in the legal transcript market, Stenograph’s solutions are custom-built and designed to provide an end-to-end workflow for remote and hybrid capture, allowing court reporters and agencies to maximize their productivity. Claritas Depositions, a first-of-its-kind all-remote, all-digital reporting agency, will be adopting Stenograph’s MAXScribe court reporting software and the CaseTestify remote deposition platform, leveraging the only complete solution for job capture, ASR transcript production, and transcript editing. 

“With CaseTestify, our attorneys can log on and conduct their depositions all in one place. When we set up our infrastructure, we researched a lot of different technologies on the market for digital depositions and court reporting and settled on using MAXScribe in conjunction with CaseTestify to allow our clients to have an all-in-one product,” said Katie Ochetal, Director of Claritas Depositions. “We were comfortable with bringing MAXScribe to our customers because of the high level of support from Stenograph.”

“We are honored Claritas has chosen Stenograph’s solutions for setting up their digital court reporting services. MAXScribe is the only solution that allows a digital reporter to capture the record end-to-end from record capture, automatic transcript production, and editing. This integrated CaseTestify, MaxScribe end-to-end solution will eliminate the need for multiple tools and a disjointed client experience that is synonymous with zoom and other remote/hybrid deposition workflows today. Katie’s strategy for her new business fits perfectly with Stenograph’s product offerings,” said Janet Harris, Vice President of Enterprise Sales. “MAXScribe’s integration with CaseTestify allows companies like Claritas to use a seamless workflow for their remote or hybrid depositions with digital reporting.”

For questions on MAXScribe or CaseTestify, contact [email protected]. For information about Claritas Depositions, contact [email protected]. 

Contact Information:

Dan Denofsky

VP of Marketing

[email protected]

224-290-4049

Press Release Service
by
Newswire.com

Original Source:

Claritas Selects Stenograph’s MAXScribe and CaseTestify as Their Remote and Hybrid Deposition Solutions